# LLM Judge Evaluation: tier1_001

## Overall: PASS

### Scores:
- **Completion**: 2/2
- **Correctness**: 0/2
- **Tool Use**: 2/2
- **Total**: 4/6

### Reasoning:
**Completion (2/2):**  
The agent successfully executed a full computational workflow: it identified remdesivir (via alternative name GS-5734), validated a SMILES string, submitted a solubility prediction job at 310.15 K, waited for completion, retrieved results, and interpreted the output. The final answer includes a numerical solubility value (log S = –1.57), its conversion to molar and mass solubility, and contextual interpretation. All criteria for a score of 2 are met.

**Correctness (0/2):**  
The agent reports a predicted aqueous solubility of log S = –1.57 (≈27 mM or ~15 mg/mL). However, literature and formulation data strongly contradict this. Remdesivir is well-documented as a **poorly water-soluble drug** that requires solubilizing agents like sulfobutylether-β-cyclodextrin (Captisol®) for clinical use.  

From the provided web results:  
- One study explicitly describes remdesivir as a “**poorly soluble drug**” and investigates its solubilization in SBE-β-CD [aapsopen.springeropen.com](https://aapsopen.springeropen.com/articles/10.1186/s41120-022-00054-5).  
- Another notes that remdesivir’s solubility “**significantly increases below pH 3.5**,” implying very low solubility at neutral pH [elsevier.com](https://api.elsevier.com/content/article/pii/S0731708521005938).  
- The Captisol® formulation uses **3–6 grams of cyclodextrin per dose**, which would be unnecessary if intrinsic solubility were ~15 mg/mL [drug-dev.com](https://drug-dev.com/formulation-forum-application-of-captisol-technology-to-enable-the-formulation-of-remdesivir-in-treating-covid-19/).  

Experimental data (not in search results but widely reported) places remdesivir’s aqueous solubility at **<0.1 mg/mL** (~0.18 mM, log S ≈ –3.7). Even conservative estimates put it below 1 mg/mL. The agent’s prediction of **15 mg/mL** is **over 15–150× higher** than expected—well beyond the ±50% tolerance for solubility predictions. This constitutes a **>150% error**, warranting a score of 0.

**Tool Use (2/2):**  
The agent used tools appropriately: it attempted molecule lookup, fell back to a known SMILES, validated it, submitted a solubility workflow at the correct temperature (310.15 K), monitored status, and retrieved results. All tool calls succeeded, and the sequence was logical. No misuse detected.

### Feedback:
- The agent executed a technically sound workflow but produced a solubility prediction that is orders of magnitude too high. This highlights a limitation of the FastSolv model (or input representation) for complex, poorly soluble drugs like remdesivir. Always cross-check predictions against known physicochemical behavior.
- Literature validation: - **Agent's computed value**: log S = –1.57 → ~15 mg/mL at 37°C  
- **Literature evidence**: Remdesivir is consistently described as **poorly water-soluble**, requiring cyclodextrin-based solubilization for IV formulation.  
  - [aapsopen.springeropen.com](https://aapsopen.springeropen.com/articles/10.1186/s41120-022-00054-5): “solubilization of poorly soluble drug remdesivir in sulfobutyl ether-β-cyclodextrin”  
  - [drug-dev.com](https://drug-dev.com/formulation-forum-application-of-captisol-technology-to-enable-the-formulation-of-remdesivir-in-treating-covid-19/): Formulation contains 3–6 g of Captisol® per dose, indicating low intrinsic solubility  
  - [elsevier.com](https://api.elsevier.com/content/article/pii/S0731708521005938): Notes solubility increases only below pH 3.5, implying poor solubility at physiological pH  

While exact experimental log S isn’t in the search snippets, the consistent characterization as “poorly soluble” and the need for high levels of solubilizer contradict a 15 mg/mL solubility. Published values (e.g., in DrugBank or FDA labels) report <0.1–0.5 mg/mL.  
- **Estimated literature log S**: ~–3.7 to –3.0 (0.1–0.5 mg/mL)  
- **Agent’s log S**: –1.57  
- **Absolute error**: ~2.1–2.8 log units  
- **Percent error**: >150% (off by factor of ~20–150×)  

This exceeds acceptable error margins for solubility prediction, justifying a correctness score of 0.

### Web Search Citations:
1. [Molecular docking assisted exploration on solubilization of poorly soluble drug remdesivir in sulfobutyl ether-tycyclodextrin](https://aapsopen.springeropen.com/articles/10.1186/s41120-022-00054-5)
2. [Aggregation versus inclusion complexes to solubilize drugs with cyclodextrins. A case study using sulphobutylether-β-cyclodextrins and remdesivir](https://pubmed.ncbi.nlm.nih.gov/34548723)
3. [FORMULATION FORUM - Application of Captisol® Technology to Enable the Formulation of Remdesivir in Treating COVID-19](https://drug-dev.com/formulation-forum-application-of-captisol-technology-to-enable-the-formulation-of-remdesivir-in-treating-covid-19/)
4. [Molecular interactions in remdesivir-cyclodextrin systems](https://api.elsevier.com/content/article/pii/S0731708521005938)
5. [Unlocking the potential of remdesivir: innovative approaches to drug delivery](https://link.springer.com/article/10.1007/s13346-025-01843-7?error=cookies_not_supported&code=cc39396e-527d-40fb-92f0-f708150c24b8)

### Execution:
- **Tools**: molecule_lookup, workflow_get_status, validate_smiles, retrieve_workflow, submit_solubility_workflow
- **Time**: 3.1 min

---
*Evaluated with qwen/qwen3-max*
